stockrowApimeds Pharmaceuticals US, Inc. (APUS) vs Sunshine Biopharma, Inc. (SBFM)
- Apimeds Pharmaceuticals US, Inc. APUS 2.69 −1.47%
- Sunshine Biopharma, Inc. SBFM 2.71 −2.87%
Apimeds Pharmaceuticals US, Inc. and Sunshine Biopharma, Inc. are both Drug Manufacturers Specialty & Generic companies. Apimeds Pharmaceuticals US, Inc. is the larger, with a market value of $4.1M against $2.1M — 1.9× the size. Apimeds Pharmaceuticals US, Inc. has the higher net margin (0.00% vs −16.5%) and the higher return on invested capital (−16.0% vs −26.7%). Across the 13 metrics below, Apimeds Pharmaceuticals US, Inc. leads on 7 and Sunshine Biopharma, Inc. on 6.
Valuation
| Metric | APUS | SBFM | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| P/E | n/m | n/m | 20.55 |
| P/S | n/m | 0.01 | 2.08 |
| P/B | 0.04 | 0.01 | 1.79 |
| Price to free cash flow | n/m | n/m | 16.29 |
| EV/EBITDA | n/m | 2.40 | 12.22 |
| EV/Sales | n/m | (0.33) | 2.87 |
| Earnings yield | (1,394.72%) | (6,843.57%) | (15.94%) |
| Free cash flow yield | (295.94%) | (2,844.26%) | 0.00% |
Profitability
| Metric | APUS | SBFM | Drug Manufacturers Specialty & Generic median |
|---|---|---|---|
| Gross margin | — | 30.30% | 53.51% |
| Operating margin | 0.00% | (16.65%) | 0.00% |
| Net margin | 0.00% | (16.50%) | (2.45%) |
| Free cash flow margin | 0.00% | (15.66%) | 0.00% |
| Return on equity | (100.13%) | (21.93%) | (0.80%) |
| Return on assets | (84.20%) | (17.78%) | (1.67%) |
| Return on invested capital | (15.96%) | (26.67%) | 0.00% |
Growth
Health
Dividend
Size
Any metric, up to five companies and an Excel export Powerpack